FibroBiologics shares surge 12.79% premarket after securing Canadian patent for fibroblast-based cachexia treatment, bolstering IP and market potential.

FibroBiologics surged 12.79% in premarket trading following the announcement of Canadian Patent No. 3118732, covering fibroblast-based treatments for cachexia. The patent strengthens the company’s intellectual property portfolio and targets a $3.2B market by 2032, emphasizing its potential to address unmet medical needs through novel immunomodulatory therapies. CEO Pete O’Heeron highlighted the milestone as a critical step toward advancing regenerative medicine for chronic diseases. The news aligns with the stock’s upward movement, underscoring investor optimism about the company’s pipeline expansion and commercial prospects. Other recent updates, such as capital raises and mixed analyst ratings, were less impactful compared to the patent filing.